X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-04-01 | BFRG | Bullfrog Ai Holdings, Inc. | Singh Vininder | CEO, 10% | S - Sale | $1.51 | -44,105 | 2,348,341 | -2% | -$66,408 | |||||
2025-04-02 | CKPT | Checkpoint Therapeutics, Inc. | Oliviero James F III | CEO, Pres, Dir | S - Sale | $4.04 | -15,090 | 3,759,929 | 0% | -$60,964 | ||||||
2025-04-01 | CKPT | Checkpoint Therapeutics, Inc. | Gray William Garrett | CFO | S - Sale | $4.05 | -12,322 | 1,446,322 | -1% | -$49,904 | ||||||
| M | 2025-04-01 | ALMS | Alumis Inc. | Colowick Alan | Dir | P - Purchase | $7.04 | +18,404 | 18,404 | New | +$129,544 | |||||
2025-04-01 | ALMS | Alumis Inc. | Babler Martin | Pres, CEO, COB | P - Purchase | $6.44 | +15,650 | 106,454 | +17% | +$100,733 | ||||||
| D | 2025-04-01 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $15.76 | -55,771 | 116,704 | -32% | -$879,008 | |||||
2025-04-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | COB, CEO | S - Sale | $123.75 | -1,500 | 440,307 | 0% | -$185,625 | ||||||
| D | 2025-04-01 | BBIO | Bridgebio Pharma, Inc. | Ellis Andrea | Dir | S - Sale+OE | $34.05 | -30,000 | 12,000 | -71% | -$1,021,500 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $35.89 | -4,369 | 27,217 | -14% | -$156,821 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $35.89 | -5,808 | 476,046 | -1% | -$208,472 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $35.89 | -5,280 | 25,471 | -17% | -$189,520 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale+OE | $35.89 | -7,541 | 42,816 | -15% | -$270,677 | |||||
| D | 2025-04-02 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | S - Sale+OE | $35.89 | -11,740 | 63,554 | -16% | -$421,396 | |||||
| D | 2025-04-01 | BGNE | Beigene, Ltd. | Wu Xiaobin | Pres, COO, GM China | S - Sale+OE | $281.40 | -51,921 | 1,192,433 | -4% | -$14,610,370 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Kathiresan Sekar | CEO | S - Sale+OE | $4.15 | -9,822 | 698,680 | -1% | -$40,761 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Nickerson Joan | Chief Administrative Officer | S - Sale+OE | $4.15 | -2,777 | 17,420 | -14% | -$11,525 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Ashe Andrew D. | See Remarks | S - Sale+OE | $4.15 | -2,681 | 348,828 | -1% | -$11,126 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Politi Jason | Chief Technical Ops. Officer | S - Sale+OE | $4.15 | -3,235 | 14,226 | -19% | -$13,425 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Dorval Allison | CFO | S - Sale+OE | $4.15 | -3,350 | 13,280 | -20% | -$13,903 | |||||
| D | 2025-04-02 | VERV | Verve Therapeutics, Inc. | Lister Troy | Chief Scientific Officer | S - Sale+OE | $4.15 | -2,189 | 6,952 | -24% | -$9,084 | |||||
| D | 2025-04-01 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Chief Program Officer | S - Sale+OE | $27.83 | -5,875 | 50,554 | -10% | -$163,486 | |||||
2025-04-02 | SYBX | Synlogic, Inc. | Dooley Mary Beth | See Remarks below | S - Sale | $1.20 | -144 | 12,901 | -1% | -$173 | ||||||
2025-04-01 | BPMC | Blueprint Medicines Corp | Haviland Kate | CEO | S - Sale | $86.65 | -2,498 | 165,929 | -1% | -$216,461 | ||||||
| D | 2025-04-02 | TLPH | Talphera, Inc. | Angotti Vincent J. | CEO | P - Purchase | $0.59 | +213,310 | 474,769 | +82% | +$125,000 | |||||
| D | 2025-04-02 | INZY | Inozyme Pharma, Inc. | Treco Douglas A | CEO, COB | S - Sale+OE | $0.89 | -8,819 | 41,046 | -18% | -$7,849 | |||||
| D | 2025-04-01 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $73.58 | -6,830 | 618,610 | -1% | -$502,577 | |||||
2025-04-02 | VTYX | Ventyx Biosciences, Inc. | Nuss John | Chief Scientific Officer | S - Sale | $1.07 | -1,887 | 467,226 | 0% | -$2,019 | ||||||
2025-04-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $15.12 | -10,000 | 121,944 | -8% | -$151,236 | ||||||
2025-04-02 | ARQT | Arcutis Biotherapeutics, Inc. | Topper David Joseph | CFO | S - Sale | $15.80 | -9,600 | 182,774 | -5% | -$151,698 | ||||||
2025-04-02 | UBX | Unity Biotechnology, Inc. | Nguyen Alexander Hieu | CLO, Head of Ops | S - Sale | $1.03 | -17,852 | 48,753 | -27% | -$18,388 | ||||||
2025-04-02 | UBX | Unity Biotechnology, Inc. | Sullivan Lynne Marie | CFO, Head of Corp. Dev. | S - Sale | $1.03 | -21,867 | 98,905 | -18% | -$22,523 | ||||||
2025-04-01 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | CFO | S - Sale | $32.54 | -6,987 | 0 | -100% | -$227,386 | ||||||
2025-04-02 | UBX | Unity Biotechnology, Inc. | Ghosh Anirvan | CEO | S - Sale | $1.03 | -96,797 | 153,454 | -39% | -$99,701 | ||||||
2025-04-01 | NUVB | Nuvation Bio Inc. | Mashal Robert | Dir | P - Purchase | $1.67 | +100,000 | 200,000 | +100% | +$166,985 | ||||||
| DM | 2025-03-31 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $100.62 | -100,590 | 105,622 | -49% | -$10,121,594 | |||||
| DM | 2025-03-31 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $100.51 | -200,650 | 9,009 | -96% | -$20,167,954 | |||||
| D | 2025-04-01 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $114.51 | -678 | 5,487 | -11% | -$77,639 | |||||
| M | 2025-03-31 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $94.92 | -35,452 | 2,981,985 | -1% | -$3,365,010 | |||||
| M | 2025-03-31 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $11.75 | +127,415 | 17,382,566 | +1% | +$1,497,322 | |||||
2025-04-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Chief Medical Officer | S - Sale | $2.49 | -952 | 53,317 | -2% | -$2,366 | ||||||
2025-04-01 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $28.38 | -500 | 73,909 | -1% | -$14,190 | ||||||
2025-03-31 | VKTX | Viking Therapeutics, Inc. | Rouan Sarah Kathryn | Dir | P - Purchase | $24.15 | +1,240 | 1,240 | New | +$29,943 | ||||||
2025-04-01 | RMTI | Rockwell Medical, Inc. | Strobeck Mark | Pres, CEO | S - Sale | $1.08 | -6,926 | 124,678 | -5% | -$7,480 | ||||||
2025-04-01 | RMTI | Rockwell Medical, Inc. | Neri Jesse | SVP, FINANCE, CFO | S - Sale | $1.10 | -886 | 30,000 | -3% | -$975 | ||||||
2025-04-01 | RMTI | Rockwell Medical, Inc. | Chole Timothy | SVP, Chief Commercial Officer | S - Sale | $1.08 | -2,868 | 46,035 | -6% | -$3,097 | ||||||
2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. | Frates James M | CFO | S - Sale | $3.47 | -10,896 | 317,519 | -3% | -$37,806 | ||||||
2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L | Chief Medical Officer | S - Sale | $3.47 | -12,425 | 194,375 | -6% | -$43,082 | ||||||
2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $3.48 | -9,192 | 187,969 | -5% | -$31,954 | ||||||
| D | 2025-03-31 | ABBV | Abbvie Inc. | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | S - Sale+OE | $210.08 | -58,832 | 54,572 | -52% | -$12,359,504 | |||||
2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale | $3.47 | -21,490 | 3,355,280 | -1% | -$74,482 | ||||||
2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale | $3.46 | -21,490 | 3,355,276 | -1% | -$74,454 | ||||||
2025-03-31 | BNTC | Benitec Biopharma Inc. | Suvretta Capital Management, LLC | Dir, 10% | P - Purchase | $12.83 | +16,497 | 1,068,701 | +2% | +$211,736 | ||||||
2025-03-31 | XOMA | Xoma Royalty Corp | Sitko Bradley | Chief Investment Officer | P - Purchase | $21.04 | +1,245 | 19,403 | +7% | +$26,201 | ||||||
2025-04-01 | XOMA | Xoma Royalty Corp | Burns Thomas M. | SVP, Finance, CFO | P - Purchase | $25.46 | +1,000 | 25,402 | +4% | +$25,460 | ||||||
2025-04-01 | AMRX | Amneal Pharmaceuticals, Inc. | Patel Gautam | Dir | S - Sale | $8.30 | -80,000 | 1,728,886 | -4% | -$664,000 | ||||||
2025-03-31 | LYEL | Lyell Immunopharma, Inc. | Brawley Otis W | Dir | P - Purchase | $0.56 | +35,640 | 35,640 | New | +$19,958 | ||||||
| M | 2025-03-28 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% | P - Purchase | $0.43 | +87,500 | 110,849,455 | 0% | +$37,521 | |||||
2025-04-01 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.65 | +100,000 | 247,447,576 | 0% | +$164,850 | ||||||
2025-04-01 | GOVX | Geovax Labs, Inc. | Dodd David A | Pres, CEO | P - Purchase | $1.08 | +10,000 | 36,661 | +38% | +$10,800 | ||||||
| D | 2025-03-31 | ASMB | Assembly Biosciences, Inc. | Bjorkquist Jeanette M | Principal Accounting Officer | S - Sale+OE | $9.85 | -180 | 4,617 | -4% | -$1,773 | |||||
| D | 2025-03-31 | ASMB | Assembly Biosciences, Inc. | Okazaki Jason A | CEO, Pres | S - Sale+OE | $9.85 | -355 | 14,757 | -2% | -$3,496 | |||||
| D | 2025-03-31 | ASMB | Assembly Biosciences, Inc. | White Nicole S | Chief Manufacturing Officer | S - Sale+OE | $9.85 | -197 | 11,674 | -2% | -$1,940 | |||||
2025-03-31 | RZLT | Rezolute, Inc. | Hogenhuis Wladimir | Dir | P - Purchase | $2.92 | +6,758 | 84,025 | +9% | +$19,733 | ||||||
2025-03-31 | SVRA | Savara Inc | Ramsay David A | Dir | P - Purchase | $2.78 | +150,000 | 2,513,642 | +6% | +$416,250 | ||||||
2025-03-28 | ZVRA | Zevra Therapeutics, Inc. | Watton Corey Michael | Dir | P - Purchase | $7.84 | +300 | 1,800 | +20% | +$2,352 | ||||||
| D | 2025-03-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $21.33 | -3,250 | 23,000 | -12% | -$69,321 | |||||
2025-03-31 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $4.78 | -25,000 | 1,355,322 | -2% | -$119,500 | ||||||
2025-03-31 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $40.75 | -15,000 | 431,795 | -3% | -$611,250 | ||||||
| D | 2025-03-27 | UBX | Unity Biotechnology, Inc. | Nguyen Alexander Hieu | CLO, Head of Ops | S - Sale+OE | $1.16 | -1,954 | 66,605 | -3% | -$2,267 | |||||
2025-03-31 | GOVX | Geovax Labs, Inc. | Reynolds Mark | CFO | P - Purchase | $1.08 | +6,800 | 14,013 | +94% | +$7,343 | ||||||
2025-03-27 | RZLT | Rezolute, Inc. | Elam Nevan C | CEO | P - Purchase | $2.85 | +12,302 | 224,119 | +6% | +$34,999 | ||||||
2025-03-27 | EOLS | Evolus, Inc. | Moatazedi David | See Remarks | S - Sale | $12.40 | -6,251 | 508,619 | -1% | -$77,512 | ||||||
| M | 2025-03-26 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% | P - Purchase | $0.44 | +15,000 | 110,761,955 | 0% | +$6,656 | |||||
2025-03-26 | NAMS | Newamsterdam Pharma Co N.V. | Topper James N | Dir | P - Purchase | $22.49 | +1,135 | 6,814,569 | 0% | +$25,521 | ||||||
2025-03-28 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.70 | +150,000 | 247,347,576 | 0% | +$254,385 | ||||||
| D | 2025-03-26 | NAMS | Newamsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | $0.00 | -16,539 | 44,000 | -27% | -$0 | |||||
| D | 2025-03-26 | NAMS | Newamsterdam Pharma Co N.V. | Davidson Michael H. | CEO | S - Sale+OE | $0.00 | -12,258 | 390,441 | -3% | -$0 | |||||
2025-03-26 | BNTC | Benitec Biopharma Inc. | Suvretta Capital Management, LLC | Dir, 10% | P - Purchase | $13.00 | +900,000 | 1,066,764 | +540% | +$11,700,000 | ||||||
| D | 2025-03-27 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $73.12 | -4,000 | 48,034 | -8% | -$292,468 | |||||
2025-03-26 | ATOS | Atossa Therapeutics, Inc. | Remmel H. Lawrence | Dir | P - Purchase | $0.70 | +10,000 | 10,257 | >999% | +$7,000 | ||||||
2025-03-26 | RZLT | Rezolute, Inc. | Evans Daron | CFO | P - Purchase | $2.89 | +20,000 | 329,900 | +6% | +$57,700 | ||||||
| M | 2025-03-25 | AKRO | Akero Therapeutics, Inc. | Graham G. Walmsley | Dir | P - Purchase | $43.94 | +200,000 | 1,202,168 | +20% | +$8,787,921 | |||||
| M | 2025-03-25 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $12.61 | +97,349 | 17,255,151 | +1% | +$1,227,309 | |||||
2025-03-25 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $36.87 | -75,000 | 6,155,851 | -1% | -$2,764,943 | ||||||
2025-03-25 | PRLD | Prelude Therapeutics Inc | Combs Andrew | Chief Chemistry Officer | P - Purchase | $0.69 | +100,000 | 480,123 | +26% | +$69,250 | ||||||
2025-03-25 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | CEO | P - Purchase | $0.69 | +675,000 | 3,669,054 | +23% | +$467,438 | ||||||
| A | 2025-03-17 | ZOM | Zomedica Corp. | Rowe Jeffrey M | Dir | P - Purchase | $0.07 | +1,439,005 | 13,679,485 | +12% | +$96,098 | |||||
2025-03-26 | ALZN | Alzamend Neuro, Inc. | Horne William B. | Dir | P - Purchase | $0.99 | +3,334 | 30,000 | +13% | +$3,285 | ||||||
| D | 2025-03-26 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $17.05 | -1,095 | 21,275 | -5% | -$18,670 | |||||
| D | 2025-03-26 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $17.05 | -3,171 | 56,889 | -5% | -$54,066 | |||||
| D | 2025-03-24 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.50 | -1,000 | 23,000 | -4% | -$22,505 | |||||
2025-03-24 | IRON | Disc Medicine, Inc. | Ashiya Mona | Dir | S - Sale | $54.11 | -5,738 | 186,541 | -3% | -$310,483 | ||||||
2025-03-24 | CYRX | Cryoport, Inc. | Sawicki Mark W | Chief Scientific Officer | S - Sale | $6.94 | -1,349 | 84,087 | -2% | -$9,364 | ||||||
2025-03-24 | CYRX | Cryoport, Inc. | Stefanovich Robert | CFO | S - Sale | $6.94 | -1,070 | 190,349 | -1% | -$7,428 | ||||||
2025-03-24 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale | $6.94 | -2,980 | 762,419 | 0% | -$20,686 | ||||||
2025-03-24 | IRON | Disc Medicine, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $54.11 | -5,738 | 186,541 | -3% | -$310,483 | ||||||
| D | 2025-03-24 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $60.58 | -421 | 9,009 | -4% | -$25,504 | |||||
2024-12-26 | XCUR | Exicure, Inc. | Hitron Systems Inc. | 10% | P - Purchase | $3.00 | +2,900,000 | 3,333,333 | +669% | +$8,700,000 | ||||||
2025-03-24 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $60.83 | -1,974 | 3,017,437 | 0% | -$120,084 | ||||||
| D | 2025-03-24 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $60.58 | -1,697 | 105,622 | -2% | -$102,804 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |